Member Info for RiskIsReward

Yes plenty of stock available, but what is the point.

We don’t sell in territories where we have approval.
We can’t sell in US where we are still awaiting for approval.

And we are running out of cash.. we need start selling soon..

https://www.google.co.uk/amp/s/finance.yahoo.com/amphtml/news/companies-genedrive-lon-gdr-could-044758294.html

I suggest people read the above, before jumping on to conclusions for placing and other prospects!!

I’m patient and still waiting to hear some good news from DB but not everyone else. So it the sp reaction

I think we already have an agreement with DIVOC who were eagerly waiting regulatory approval from ICMR for last 6 months now..

I would expect some initial sales by now if they were so desperate

Market sentiments is weak and investors are selling and moving elsewhere.
Simple reason is no material sales/revenue in last 12 months. The overall market is also not looking and the radio silence from DB is not not helping.
We need some material RNS to reverse the current trend.

Db always concentrated for big bucks from USA with BC collaboration, just like us investors who dream for 10 and 20 bags.
Which all went little pear shaped with FDA EUA delayed
As a product we are best placed to sell with ICMR validation, It gave us good opportunity to bounce back lets wait and see what DB does this time.

Absolutely agree with Pacman and Sally both, Tests are always in demand since the pandemic has begun.
We are the best product, our case studies and ICMR evaluation is a testament for this.

When it comes to sales they are lot of products who are try to claim themselves to be best and sell a lot than us. Sales is completely different ball game and our track record in that is not great till date.
I hope DB would improve soon and start sell something.

With the respect to India Sales:
It is full of private labs with a highly competitive market where prices are capped by govt and lot of cheaper tests available. Unless GDR product offers extra savings to labs there wont be any takers. (simple question why would any business update to newer tests of good quality only to reduce the profits)
I'm sure DB can work out this and sell some soon.

When you have a potential double digit million deal on table which you’re trying to negotiate over last 8 months and still positive to achieve it as per last presentation..
Plus lots of others products commercialised and distributors lined up and ready for sale.
plus with 8 months worth money in bank with no debt..

At this juncture they would not raise money.. if they do so it is a disaster and I think it would hit less than what ever placing price is.

Genedrive® 96 SARS-CoV-2 Kit achieved 100% sensitivity and 100% specificity in the performance evaluation, so Our is a premium product and cannot b compared with cheap products avaialble at the cheap prices.

Wording from RNS States
"The country has also introduced pricing controls into the public market, setting a dynamic that does favour the provision of "basic" tests. The Company believes however that formal performance evaluation data and ICMR approval will contribute positively to commercial efforts and premium products such as gendrive's can play a part in the need for COVID-19 testing."

in the performance evaluation conducted by the ICMR. The Company will now commence commercial activities in India through its existing distributor Divoc Health and will also be seeking additional routes to the market.

Is poor from GDR, no RNS on India opportunity or UNICEF. looks like DB is not bothered about PI’s
Anyways the major catalyst would be FDA or EU deal or POC.
Things are looking a bit better now, best time for FDA to land

I’m saying they are all not buys like you think..
don’t mislead others by saying heavy buying. you know very well that any thing above median price is classified as Buy by Algorithms.
But in reality, today I could generate a sell above median during most part of the day..

This is bull**** anything which is less than 66.80 is sell..
I just generated sell quote for 66.80
This is just manipulative stuff from MM’s, I surprised your are promoting these buys!!

How come the said EU Country is still using old provider for last 6 months and still think about GDR, it is about time DB gives give us clarity like what is stopping them to sign the deal.

In india you can get a pcr test as cheap as 800 inr which is £8..
Prices are capped by governament in india.
https://www.timesnownews.com/india/article/covid-19-how-much-does-rt-pcr-test-cost-find-state-wise-price-here/686056

Secondly PCR testing is so competitive that getting new machine and changing workflows are super expensive and not justifiable at the moment.
https://www.hindustantimes.com/cities/delhi-news/delhi-covid-19-testing-labs-at-capacity-home-collections-hit-101618256546274.html

Looks like we missed India, Even with approval GDr wont be able to do generate much sales in India.

we need some revenue generating RNS with numbers before the FDA EUA.
Could’ve be either the EU deal or some numbers from PHE or US DOD.
First RNS is out..
I’m waiting for next one..

Lol... just read my past again.. I meant Monday morning..

It is good we are getting mentioned and the sentiment is returning. But don’t be disappointed if there is no RNS tomorrow, this is certainly a good news!!

Look at all the 2021 approvals either they are multi analyte Pcr tests or POC or Home collection kits
GDR is multi analyte, I have got some hope this month we may see FDA EUA